- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...
Astellas Pharma and Poseida Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...
BioArctic AB (publ) announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new t...
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
FibroBiologics, , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...
Observation: ACROBiosystems' relentless commitment to innovation and strategic partnerships underscores its pivotal role in advancing organoid research and...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collabo...
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in ...
UroGen Pharma has initiated legal proceedings against pharmaceutical giant Teva over what they're dubbing as "Totally Mundane" Cancer Treatment Patents. Ur...
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced th...
© 2024 Biopharma Boardroom. All Rights Reserved.
